Calcium antagonists and the diabetic patient: A response to recent controversies

American Journal of Cardiology

Volumn 82, Issue 9 SUPPL. 1, 1998, Pages 40-41

  Poulter, Neil R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

EID: 0032511971     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(98)00757-7     Document Type: Article

References (18)

1. Lindberg G, Bingefors K, Ranstam J, Rastam L, Melander A. Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study. Br Med J 1998;316:741-745.
2. Byington RP, Craven T, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997;350:1075-1076.
3. Pahor M. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1-7.
4. Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first-line antihypertensive agents. Am J Hypertens 1996;9:122-125.
5. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
6. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Ragunathan TE, Weiss NS, Rosendall FR, Lemaitre RN, Smith NL, Wahl PW, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
7. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995;155:2150-2156.
8. Epstein M. Calcium antagonists: still appropriate as first-line antihypertensive agents. Am J Hypertens 1996;9:110-121.
9. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organisation and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hum Hypertens 1997;11:331-342.
10. Cutler JA. Calcium-channel blockers for hypertension - uncertainty continues. N Engl J Med 1998;338:679-681.
11. Tatti P, Pahor M, Byington RP, DiMauro P, Gaurisco R, Strollo G, Strollo F. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomised Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-602.
12. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-652.
13. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998;351:689-690.
14. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; November 1997: NIH Publication No. 98-4080.
15. Joint BCS/BHA/BHS Working Party on Coronary Prevention. Joint British Recommendations on Prevention of Coronary Heart Disease in Clinical Practice. Heart 1998; in press.
16. th Annual Meeting and Scientific Sessions, June 11-16, 1998. Abstract 0210.
17. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764.
18. Davis BR, Cutler JA, Gordon DJ. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 1996;9:342-360.